Rigel Pharmaceuticals (RIGL)
Market Price (3/30/2026): $25.82 | Market Cap: $470.2 MilSector: Health Care | Industry: Biotechnology
Rigel Pharmaceuticals (RIGL)
Market Price (3/30/2026): $25.82Market Cap: $470.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 78%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 74%, FCF Yield is 16% | Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% | Key risksRIGL key risks include [1] intense commercial competition from larger, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 64% | |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43% | |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26% | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 78%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 74%, FCF Yield is 16% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 64% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20% |
| Key risksRIGL key risks include [1] intense commercial competition from larger, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Lower-than-expected 2026 revenue guidance, primarily due to a significant decline in contract revenue, caused investor concern. Rigel Pharmaceuticals projected full-year 2026 total revenue to be between $275 million and $290 million. This outlook implied an approximate 4% year-over-year decrease at the midpoint when compared to the $294.3 million in total revenue reported for 2025. The anticipated decline in 2026 was largely driven by an expected 64% year-over-year drop in contract revenue, from $62.3 million in 2025 to $20 million - $25 million in 2026, as 2025's figures included a one-time $40 million non-cash revenue from an agreement with Eli Lilly and Company. While net product sales were forecast to grow by about 11% year-over-year, this was not enough to offset the reduction in contract revenue.
2. The company missed analyst consensus estimates for its fourth-quarter 2025 earnings per share (EPS). Rigel reported a Q4 2025 EPS of $1.14, which fell short of analysts' consensus estimates of $1.33 by $0.19. This earnings miss, despite total revenue for the quarter exceeding expectations at $69.8 million, likely contributed to negative sentiment among investors.
Show more
Stock Movement Drivers
Fundamental Drivers
The -48.9% change in RIGL stock from 11/30/2025 to 3/29/2026 was primarily driven by a -84.1% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 50.49 | 25.81 | -48.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 282 | 294 | 4.3% |
| Net Income Margin (%) | 40.2% | 124.7% | 210.5% |
| P/E Multiple | 8.0 | 1.3 | -84.1% |
| Shares Outstanding (Mil) | 18 | 18 | -1.0% |
| Cumulative Contribution | -48.9% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RIGL | -48.9% | |
| Market (SPY) | -5.3% | 21.6% |
| Sector (XLV) | -8.7% | 35.7% |
Fundamental Drivers
The -33.6% change in RIGL stock from 8/31/2025 to 3/29/2026 was primarily driven by a -82.0% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 38.85 | 25.81 | -33.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 268 | 294 | 9.8% |
| Net Income Margin (%) | 36.5% | 124.7% | 241.6% |
| P/E Multiple | 7.1 | 1.3 | -82.0% |
| Shares Outstanding (Mil) | 18 | 18 | -1.8% |
| Cumulative Contribution | -33.6% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RIGL | -33.6% | |
| Market (SPY) | 0.6% | 13.3% |
| Sector (XLV) | 5.2% | 27.8% |
Fundamental Drivers
The 11.9% change in RIGL stock from 2/28/2025 to 3/29/2026 was primarily driven by a 4960.5% change in the company's Net Income Margin (%).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.06 | 25.81 | 11.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 157 | 294 | 86.9% |
| Net Income Margin (%) | 2.5% | 124.7% | 4960.5% |
| P/E Multiple | 104.6 | 1.3 | -98.8% |
| Shares Outstanding (Mil) | 18 | 18 | -3.4% |
| Cumulative Contribution | 11.9% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RIGL | 11.9% | |
| Market (SPY) | 9.8% | 23.3% |
| Sector (XLV) | -2.1% | 28.4% |
Fundamental Drivers
The 70.9% change in RIGL stock from 2/28/2023 to 3/29/2026 was primarily driven by a 229.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.10 | 25.81 | 70.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 89 | 294 | 229.3% |
| P/S Multiple | 2.9 | 1.6 | -45.3% |
| Shares Outstanding (Mil) | 17 | 18 | -5.1% |
| Cumulative Contribution | 70.9% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RIGL | 70.9% | |
| Market (SPY) | 69.4% | 24.7% |
| Sector (XLV) | 18.4% | 24.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RIGL Return | -24% | -43% | -3% | 16% | 155% | -38% | -25% |
| Peers Return | -33% | -38% | -29% | -55% | -48% | 8% | -93% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| RIGL Win Rate | 33% | 33% | 42% | 42% | 58% | 0% | |
| Peers Win Rate | 31% | 44% | 44% | 36% | 50% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| RIGL Max Drawdown | -33% | -75% | -52% | -47% | -3% | -41% | |
| Peers Max Drawdown | -40% | -52% | -49% | -60% | -61% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, AKTS, ALPS, DCOY, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | RIGL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -86.4% | -25.4% |
| % Gain to Breakeven | 635.5% | 34.1% |
| Time to Breakeven | 1,111 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -57.6% | -33.9% |
| % Gain to Breakeven | 135.8% | 51.3% |
| Time to Breakeven | 118 days | 148 days |
| 2018 Correction | ||
| % Loss | -64.8% | -19.8% |
| % Gain to Breakeven | 183.7% | 24.7% |
| Time to Breakeven | 477 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -84.6% | -56.8% |
| % Gain to Breakeven | 551.0% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to VRTX, AKTS, ALPS, DCOY, DFTX
In The Past
Rigel Pharmaceuticals's stock fell -86.4% during the 2022 Inflation Shock from a high on 2/8/2021. A -86.4% loss requires a 635.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Rigel Pharmaceuticals (RIGL)
AI Analysis | Feedback
Here are 1-3 brief analogies for Rigel Pharmaceuticals (RIGL):
- Like a Vertex Pharmaceuticals for rare blood and immune diseases.
- A Gilead Sciences specializing in small molecule drugs for immune and blood disorders.
AI Analysis | Feedback
```html- Tavalisse: An oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
- Fostamatinib: A drug in phase III clinical trials for warm autoimmune hemolytic anemia and for the treatment of COVID-19.
- R289: An oral interleukin receptor associated kinase 1/4 inhibitor in phase I clinical trials for autoimmune, inflammatory, and hematology-oncology diseases.
- R552: A receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trials for autoimmune and inflammatory diseases.
AI Analysis | Feedback
Rigel Pharmaceuticals, Inc. (RIGL) primarily sells its intellectual property and rights to its drug candidates to other pharmaceutical and biotechnology companies through various licensing, research, and collaboration agreements. It also sells its commercialized product, Tavalisse, to the pharmaceutical supply chain (e.g., wholesalers, distributors, specialty pharmacies).
Based on the provided description, the major identifiable customers or partners that provide revenue to Rigel Pharmaceuticals through licensing, collaboration, and research agreements include:
- AstraZeneca AB (Symbol: AZN)
- BerGenBio AS (Symbol: BGBIO.OL)
- Daiichi Sankyo (Symbol: DSNKY)
- Kissei Pharmaceutical Co., Ltd. (Symbol: KSPHF)
- Eli Lilly and Company (Symbol: LLY)
AI Analysis | Feedback
nullAI Analysis | Feedback
Raul R. Rodriguez, President and Chief Executive Officer
Raul R. Rodriguez joined Rigel Pharmaceuticals in April 2000, progressing through various business development and operational roles before being appointed President and Chief Executive Officer in November 2014. Earlier in his career, Mr. Rodriguez served as Chief Operating Officer of Ontogeny, an executive officer at Sense Technologies, and a director at Scios. He also held various positions at Searle Pharmaceuticals. He holds an MBA from Stanford University and an MPH from the University of Illinois.
Dean Schorno, C.P.A., Executive Vice President and Chief Financial Officer
Dean Schorno was appointed Executive Vice President and Chief Financial Officer in May 2018. Before joining Rigel, Mr. Schorno served as CFO of 23andMe, Inc. from 2015. His prior experience includes CFO roles at Adaptive Biotechnologies and Genomic Health, where he managed financial operations during periods of significant business and commercial growth, including financing and commercial transactions. Earlier in his career, he founded and led a CPA and consulting firm. Mr. Schorno is a Certified Public Accountant.
David A. Santos, Executive Vice President and Chief Commercial Officer
David A. Santos became Executive Vice President and Chief Commercial Officer in August 2020. He joined Rigel from Jazz Pharmaceuticals, where he was the Hematology/Oncology Business Unit Head, responsible for leading US commercialization of the oncology portfolio and overseeing three successful product launches. Previously, Mr. Santos held roles as Vice President of Sales and Marketing for Medivation (now Pfizer) and Vice President, Kinase Inhibitor Franchise for Onyx (now Amgen). He also spent nearly nine years at Genentech, Inc. (now a member of the Roche Group), where he held key commercial leadership positions for brands such as Avastin, Herceptin, and Tarceva.
Lisa Rojkjaer, M.D., Executive Vice President and Chief Medical Officer
Dr. Lisa Rojkjaer was appointed Executive Vice President and Chief Medical Officer in March 2024. She brings over 20 years of experience in clinical development, regulatory affairs, and medical affairs, with a specialization in hematology and oncology. Prior to Rigel, Dr. Rojkjaer served as Chief Medical Officer of Sangamo Therapeutics. Her previous roles also include Chief Medical Officer at Viracta Therapeutics and Nordic Nanovector, and Global Clinical Program Head at Novartis Pharmaceuticals.
Raymond J. Furey, Executive Vice President, General Counsel and Corporate Secretary
Raymond J. Furey was appointed Executive Vice President, General Counsel and Corporate Secretary in December 2022. Before joining Rigel, Mr. Furey was Senior Vice President, Chief Compliance Officer, and Interim General Counsel at Turning Point Pharmaceutics. He also previously served as Chief Operating Officer at Ara Pharmaceuticals. Earlier in his career, Mr. Furey held positions at OSI Pharmaceuticals and Genentech.
AI Analysis | Feedback
Key Risks to Rigel Pharmaceuticals (RIGL)
Clinical Trial and Regulatory Approval Risk: Rigel Pharmaceuticals' future growth and financial performance are heavily dependent on the successful completion of clinical trials and subsequent regulatory approvals for its pipeline candidates. Most notably, Fostamatinib is currently in multiple Phase III clinical trials for indications such as warm autoimmune hemolytic anemia and COVID-19. Any failure to achieve positive results in these trials, or an inability to obtain regulatory approval, would significantly hinder the company's ability to bring new products to market and generate revenue.
Commercialization and Market Adoption Risk for Tavalisse and Future Products: While Tavalisse is an approved product, its ongoing commercial success and market penetration are crucial for the company's current revenue. Similarly, should pipeline candidates like Fostamatinib gain regulatory approval, their commercial success will depend on factors such as market acceptance, physician adoption, competitive landscape, pricing, and reimbursement. Failure to achieve significant market uptake for Tavalisse or future approved products would negatively impact revenue and profitability.
Reliance on Collaborative Partnerships: Rigel Pharmaceuticals has entered into numerous research, license, and strategic collaboration agreements with other pharmaceutical companies, including AstraZeneca, BerGenBio, Daiichi Sankyo, Kissei Pharmaceutical, and Eli Lilly and Company. The progress and potential success of several of its pipeline assets (e.g., R256, AXL inhibitors, murine double minute 2 inhibitors, R552) are reliant on these partnerships. Any disputes, termination of agreements, or insufficient commitment from partners could delay or halt the development and commercialization of these programs, impacting Rigel's long-term prospects.
AI Analysis | Feedback
nullAI Analysis | Feedback
Rigel Pharmaceuticals (RIGL) operates in therapeutic areas with significant addressable markets for its main products.
For Tavalisse (fostamatinib), which is approved for chronic immune thrombocytopenia (ITP), the global market size for Immune Thrombocytopenia (ITP) treatment was valued at approximately USD 3.14 billion in 2024, with projections to reach around USD 4.53 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.4%. Another estimate places the global ITP market size at USD 3.57 billion in 2025, expected to exceed USD 4.53 billion by 2035, with a CAGR of over 2.4% during the period of 2026-2035. The U.S. market alone for Immune Thrombocytopenia exceeded USD 1.87 billion in 2023.
For Fostamatinib, which is in clinical trials for warm autoimmune hemolytic anemia (wAIHA), the global warm autoimmune hemolytic anemia (wAIHA) treatment market was valued at USD 430 million in 2024 and is projected to grow to USD 680 million by 2032, exhibiting a CAGR of 5.8%. Other estimates indicate the global wAIHA treatment sector to be valued at USD 767.53 million in 2025, with a forecast to reach USD 1.92 billion by 2035 at a CAGR of 9.6%. Another report estimated the global market to be USD 4.98 billion in 2025, growing to USD 7.24 billion by 2032, with a CAGR of 5.5%. The U.S. market size for wAIHA treatment was estimated at USD 198 million in 2024.
AI Analysis | Feedback
Rigel Pharmaceuticals (RIGL) is anticipated to drive future revenue growth over the next two to three years primarily through the sustained commercial performance and expansion of its key marketed products. The company has explicitly highlighted its focus on commercial expansion and execution, which is expected to fuel top-line growth. Here are the expected drivers of future revenue growth: * Continued Growth of TAVALISSE Sales: TAVALISSE (fostamatinib disodium hexahydrate), approved for chronic immune thrombocytopenia (ITP), remains Rigel's primary revenue generator and is expected to continue its strong sales momentum. The company anticipates continued growth, driven by sustained new patient demand and ongoing commercial and marketing infrastructure expansion. TAVALISSE net product sales reached $104.8 million in 2024 and are a significant contributor to overall product sales growth. * Increasing Contributions from REZLIDHIA Sales: REZLIDHIA (olutasidenib), used for relapsed or refractory mutant-IDH1 acute myeloid leukemia (AML), is a growing oncology asset that is expanding and diversifying Rigel's revenue base. REZLIDHIA sales have demonstrated significant year-over-year growth and are expected to continue to contribute to the company's net product sales. * Growing Sales of GAVRETO: GAVRETO (pralsetinib), acquired by Rigel in 2024 for RET fusion-positive non-small cell lung cancer (NSCLC) and advanced or metastatic thyroid cancer, is a key addition to the commercial portfolio. This product is making a substantial contribution to Rigel's sales and is highly synergistic with its existing infrastructure, further supporting top-line growth.AI Analysis | Feedback
Share Issuance
- Rigel Pharmaceuticals' shares outstanding increased from 0.017 billion in Q1 2021 to 0.019 billion in Q3 2025.
- The number of shares outstanding increased by 6.52% in one year.
- A reverse stock split with a ratio of 1:10 occurred on June 27, 2024.
Inbound Investments
- Rigel Pharmaceuticals has strategic development collaborations and license agreements with various partners, including AstraZeneca AB, BerGenBio AS, Daiichi Sankyo, Kissei Pharmaceutical Co., Ltd., and Eli Lilly and Company. These agreements often involve upfront and milestone payments to Rigel.
Capital Expenditures
- Rigel Pharmaceuticals reported capital expenditures of $73K in Q4 2022.
- Capital expenditures were -$38K in the last 12 months, as of the current time (March 2026), suggesting very low capital spending or net proceeds from asset disposals.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Rigel Pharmaceuticals Earnings Notes | 12/16/2025 | |
| How Low Can Rigel Pharmaceuticals Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to RIGL.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 16.54 |
| Mkt Cap | 0.5 |
| Rev LTM | 147 |
| Op Inc LTM | 60 |
| FCF LTM | 36 |
| FCF 3Y Avg | 10 |
| CFO LTM | 36 |
| CFO 3Y Avg | 13 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 36.5% |
| Rev Chg 3Y Avg | 24.3% |
| Rev Chg Q | 15.4% |
| QoQ Delta Rev Chg LTM | 3.3% |
| Op Mgn LTM | 40.3% |
| Op Mgn 3Y Avg | 18.8% |
| QoQ Delta Op Mgn LTM | 19.6% |
| CFO/Rev LTM | 28.0% |
| CFO/Rev 3Y Avg | 16.7% |
| FCF/Rev LTM | 26.2% |
| FCF/Rev 3Y Avg | 12.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.5 |
| P/S | 5.4 |
| P/EBIT | 3.6 |
| P/E | 1.3 |
| P/CFO | 6.2 |
| Total Yield | 3.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.7% |
| D/E | 0.0 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -17.9% |
| 3M Rtn | -6.4% |
| 6M Rtn | 5.3% |
| 12M Rtn | 12.1% |
| 3Y Rtn | 28.8% |
| 1M Excs Rtn | -8.4% |
| 3M Excs Rtn | 1.7% |
| 6M Excs Rtn | 8.9% |
| 12M Excs Rtn | 0.6% |
| 3Y Excs Rtn | -29.7% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA215814 | REZLIDHIA | olutasidenib | capsule | 12012022 | 136.8% | 104.6% | 59.3% | 303.6% | 277.3% |
| NDA213721 | GAVRETO | pralsetinib | capsule | 9042020 | 33.3% | 66.2% | 75.3% | -38.1% | 11.7% |
| NDA209299 | TAVALISSE | fostamatinib disodium | tablet | 4172018 | -31.1% | -22.4% | -43.6% | -60.3% | -37.2% |
Price Behavior
| Market Price | $25.81 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 11/29/2000 | |
| Distance from 52W High | -49.4% | |
| 50 Days | 200 Days | |
| DMA Price | $32.43 | $32.90 |
| DMA Trend | up | down |
| Distance from DMA | -20.4% | -21.6% |
| 3M | 1YR | |
| Volatility | 50.5% | 69.7% |
| Downside Capture | 1.19 | 0.77 |
| Upside Capture | -74.12 | 129.59 |
| Correlation (SPY) | 20.9% | 22.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.53 | 1.05 | 1.40 | 0.87 | 0.86 | 1.35 |
| Up Beta | 0.32 | 1.98 | 1.45 | 0.81 | 0.63 | 0.83 |
| Down Beta | 2.96 | 1.09 | 0.76 | 0.00 | 0.67 | 1.17 |
| Up Capture | 152% | -16% | 44% | 95% | 167% | 707% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 13 | 20 | 27 | 56 | 121 | 353 |
| Down Capture | 140% | 167% | 256% | 141% | 104% | 111% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 8 | 20 | 33 | 66 | 127 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RIGL | |
|---|---|---|---|---|
| RIGL | 34.8% | 69.6% | 0.70 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 28.6% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 22.2% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 3.4% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -5.2% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 21.4% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RIGL | |
|---|---|---|---|---|
| RIGL | -9.1% | 86.0% | 0.30 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 21.7% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 24.9% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 2.8% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 1.7% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 24.6% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RIGL | |
|---|---|---|---|---|
| RIGL | 2.2% | 82.8% | 0.39 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 26.0% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 28.0% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 1.2% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 7.4% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 22.6% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/3/2026 | -10.3% | -13.9% | |
| 11/4/2025 | 33.4% | 33.7% | 72.4% |
| 8/5/2025 | 23.0% | 42.4% | 65.6% |
| 3/4/2025 | -8.1% | -11.7% | -17.5% |
| 11/7/2024 | 42.9% | 77.8% | 50.0% |
| 8/6/2024 | 5.8% | 35.8% | 43.7% |
| 3/5/2024 | 5.4% | 0.7% | -12.8% |
| 11/7/2023 | 2.2% | -2.3% | 31.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 10 | 10 |
| # Negative | 8 | 9 | 8 |
| Median Positive | 8.5% | 17.1% | 31.0% |
| Median Negative | -6.0% | -8.7% | -15.2% |
| Max Positive | 42.9% | 77.8% | 72.4% |
| Max Negative | -11.0% | -13.9% | -26.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/04/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/03/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/3/2026 | Prior: Q4 2025 Earnings Reported 1/12/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 275.00 Mil | 282.50 Mil | 290.00 Mil | 0 | Affirmed | Guidance: 282.50 Mil for 2026 | |
| 2026 Net Product Sales | 255.00 Mil | 260.00 Mil | 265.00 Mil | 0 | Affirmed | Guidance: 260.00 Mil for 2026 | |
| 2026 Contract Revenues | 20.00 Mil | 22.50 Mil | 25.00 Mil | 0 | Affirmed | Guidance: 22.50 Mil for 2026 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Schorno, Dean L | EVP & Chief Financial Officer | Direct | Sell | 2062025 | 20.92 | 2,036 | 42,595 | 1,233,690 | Form |
| 2 | Schorno, Dean L | EVP & Chief Financial Officer | Direct | Sell | 2062025 | 21.93 | 1,734 | 38,020 | 1,254,935 | Form |
| 3 | Santos, David A | EVP, Chief Commercial Officer | Direct | Sell | 2062025 | 20.92 | 2,125 | 44,457 | 1,119,274 | Form |
| 4 | Santos, David A | EVP, Chief Commercial Officer | Direct | Sell | 2062025 | 21.93 | 1,796 | 39,379 | 1,133,662 | Form |
| 5 | Rodriguez, Raul R | CEO, President | Direct | Sell | 2062025 | 20.92 | 4,952 | 103,601 | 5,101,670 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.